AbbVie Inc.
ABBV
Rankning i aktier
#25
AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery,... AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adult patients. Oncology and Hematology: For blood cancers, AbbVie provides IMBRUVICA and VENCLEXTA (a BCL-2 inhibitor), both indicated for adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Virology: MAVYRET offers a treatment option for individuals with chronic HCV genotype 1-6 infection. Gastroenterology and Endocrinology: The company supplies CREON, an enzyme replacement therapy for exocrine pancreatic insufficiency, and Synthroid, used to manage hypothyroidism. Linzess/Constella helps treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation. Women's Health and Urology: Lupron serves as a palliative treatment for conditions like advanced prostate cancer, endometriosis, central precocious puberty, and anemia caused by uterine fibroids. ORILISSA, a nonpeptide small molecule GnRH antagonist, is designed for women experiencing moderate to severe endometriosis pain. Neurology: AbbVie offers Duopa and Duodopa, a levodopa-carbidopa intestinal gel for Parkinson's disease, and Ubrelvy to treat migraines (with or without aura) in adults. The therapeutic formulation of Botox is also part of its offerings. Ophthalmology: Its eye care segment features Lumigan/Ganfort (a bimatoprost ophthalmic solution) and Alphagan/Combigan (an alpha-adrenergic receptor agonist), both aimed at reducing elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension. Restasis, a calcineurin inhibitor immunosuppressant, is provided to enhance tear production, alongside other specialized eye care products. AbbVie Inc. also engages in research collaborations, including a partnership with Dragonfly Therapeutics, Inc. The company was founded in 2012 and operates from its headquarters in North Chicago, Illinois.
Aktiekurs
$282.96
Senast synkroniserad: 2026-10-19
Marknadsvärde
$500.02B
Förändring (1 dag)
-0.75%
Förändring (1 år)
22.62%
Land
US
Handel AbbVie Inc. (ABBV)
Kategori
Healthcare
P/B-tal för AbbVie Inc. (ABBV)
P/B-tal per February 2026 TTM: -156.00
Enligt AbbVie Inc. senaste finansiella rapporter och aktiekurs är det aktuella P/B-talet (TTM) -156.00. I slutet av 2026 hade företaget ett P/B-tal på 0.
Historik för P/B-tal för AbbVie Inc. från 2026 till 2026
P/B-tal vid årets slut
| År | P/B-tal | Ändra |
|---|---|---|
| Inte tillräckligt med data för de angivna datumen. | ||
P/B-tal för liknande företag eller konkurrenter
| Företag | P/B-tal | Skillnad i P/B-tal | Land |
|---|---|---|---|
| 31.9092 | -120.45% |
US
|
|
| 7.3138 | -104.69% |
US
|
|
| 8.6873 | -105.57% |
US
|
|
| 8.4776 | -105.43% |
CH
|
|
| 6.754 | -104.33% |
CH
|
